Vireo Growth closes $49M Colorado retail acquisition
What's the deal? Vireo Growth has formally closed its acquisition of certain Colorado retail assets from PharmaCann for approximately $49 million. The purchase transferred 17 operational dispensaries, plus leases, licenses, inventory, and intellectual property tied to the LivWell brand.
What are the terms? The consideration was structured as Vireo subordinate voting shares plus the assumption of certain liabilities, with closing adjustments for inventory and trade payables. The deal lifts Vireo's Colorado retail count to 56 operational locations.
Why now? Vireo operated the acquired sites under a Management Services Agreement from March through August 2026, giving its team time to learn staffing, systems, and supply chains before taking ownership. Chief executive officer John Mazarakis said the approach validated the company's integration model, with further performance gains expected once the sites are fully absorbed.
The credit line: Vireo also disclosed a senior secured asset-based revolving credit facility arranged through Bank of MontrealDealroom has a profile for this one. Try Dealroom →. The facility opens with a $65 million commitment, expandable to $85 million and then $105 million via a $20 million accordion feature. The five-year revolver is secured by substantially all assets of Vireo's non-cannabis subsidiaries.
Pricing is set at SOFR plus a margin of 1.75% to 2%, or the base rate plus 0.75% to 1%, with an unused commitment fee of 0.25% annually. Proceeds may fund working capital, capital expenditures, permitted acquisitions, and refinancing of subsidiary debt.
What's the endgame? In early August 2026, Vireo disclosed a four-deal entry into Ohio and a planned acquisition of Planet 13 HoldingsDealroom has a profile for this one. Try Dealroom →. It now reports operations across 10 states and more than 170 dispensaries.
What could go wrong? Colorado is the near-term test: a mature, price-compressed adult-use market that has squeezed margins across the industry. Vireo's Q2 2026 earnings call on August 11, 2026 is the first opportunity to weigh hard numbers against the growth plan.
The signal: Bank-led revolving credit inside a cannabis-adjacent structure, priced closer to investment-grade spreads, suggests institutional capital is finding workable routes into the sector without waiting for federal reform.
Read more: Highly Capitalized
Image credit: Generated with Gemini
